Literature DB >> 17108139

Enhanced antitumor response by divergent modulation of natural killer and natural killer T cells in the liver.

Jeff J Subleski1, Veronica L Hall, Timothy C Back, John R Ortaldo, Robert H Wiltrout.   

Abstract

The use of interleukin-18 (IL-18) together with IL-12 induced high levels of IFN-gamma in tumor-bearing mice and regression of liver tumors that was abolished in IFN-gamma((-/-)) mice. Natural killer (NK) and NKT cells were the major producers of IFN-gamma in the livers of mice treated with IL-18 and/or IL-12. Liver NK cells were significantly increased by treatment with IL-18/IL-12, whereas the degree of liver NKT cell TCR detection was diminished by this treatment. Reduction of NK cells with anti-asGM1 decreased the antitumor activity of IL-18/IL-12 therapy and revealed NK cells to be an important component for tumor regression in the liver. In contrast, the antitumor effects of both IL-18 and IL-12 were further increased in CD1d((-/-)) mice, which lack NKT cells. Our data, therefore, show that the antitumor activity induced in mice by IL-18/IL-12 is NK and IFN-gamma dependent and is able to overcome an endogenous immunosuppressive effect of NKT cells in the liver microenvironment. These results suggest that immunotherapeutic approaches that enhance NK cell function while eliminating or altering NKT cells could be effective in the treatment of cancer in the liver.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17108139     DOI: 10.1158/0008-5472.CAN-06-0811

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  36 in total

1.  Editorial: NKT cells: to suppress or not to suppress, that is the question.

Authors:  Jeff J Subleski; John R Ortaldo
Journal:  J Leukoc Biol       Date:  2009-10       Impact factor: 4.962

Review 2.  NK cells in immunotolerant organs.

Authors:  Haoyu Sun; Cheng Sun; Zhigang Tian; Weihua Xiao
Journal:  Cell Mol Immunol       Date:  2013-04-08       Impact factor: 11.530

3.  Expression of blood serum proteins and lymphocyte differentiation clusters after chronic occupational exposure to ionizing radiation.

Authors:  Valentina L Rybkina; Tamara V Azizova; Harry Scherthan; Viktor Meineke; Harald Doerr; Galina V Adamova; Olga V Teplyakova; Sergey V Osovets; Maria V Bannikova; Alexander V Zurochka
Journal:  Radiat Environ Biophys       Date:  2014-07-30       Impact factor: 1.925

4.  NKT cells act through third party bone marrow-derived cells to suppress NK cell activity in the liver and exacerbate hepatic melanoma metastases.

Authors:  Leila Sadegh; Peter W Chen; Joseph R Brown; Zhiqiang Han; Jerry Y Niederkorn
Journal:  Int J Cancer       Date:  2015-02-27       Impact factor: 7.396

Review 5.  A push-pull vaccine strategy using Toll-like receptor ligands, IL-15, and blockade of negative regulation to improve the quality and quantity of T cell immune responses.

Authors:  Jay A Berzofsky
Journal:  Vaccine       Date:  2011-11-21       Impact factor: 3.641

6.  Serum-based tracking of de novo initiated liver cancer progression reveals early immunoregulation and response to therapy.

Authors:  Jeff J Subleski; Anthony J Scarzello; W Gregory Alvord; Qun Jiang; Jimmy K Stauffer; Anthony Kronfli; Bahara Saleh; Timothy Back; Jonathan M Weiss; Robert H Wiltrout
Journal:  J Hepatol       Date:  2015-07-02       Impact factor: 25.083

Review 7.  STAT proteins - key regulators of anti-viral responses, inflammation, and tumorigenesis in the liver.

Authors:  Bin Gao; Hua Wang; Fouad Lafdil; Dechun Feng
Journal:  J Hepatol       Date:  2012-04-12       Impact factor: 25.083

8.  Thymic and peripheral microenvironments differentially mediate development and maturation of iNKT cells by IL-15 transpresentation.

Authors:  Eliseo F Castillo; Luis F Acero; Spencer W Stonier; Dapeng Zhou; Kimberly S Schluns
Journal:  Blood       Date:  2010-06-25       Impact factor: 22.113

Review 9.  The role of NKT cells in tumor immunity.

Authors:  Masaki Terabe; Jay A Berzofsky
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

Review 10.  Immunotherapy of cancer by IL-12-based cytokine combinations.

Authors:  Jonathan M Weiss; Jeff J Subleski; Jon M Wigginton; Robert H Wiltrout
Journal:  Expert Opin Biol Ther       Date:  2007-11       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.